Targacept/GSK identify lead compound in anti-smoking program « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
May 2008

M T W T F S S

« Apr Jun »

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30 31

Targacept/GSK identify lead compound in anti-smoking program

Posted on May 5, 2008 by crimsoncanary

Targacept, in collaboration with GSK, have identified a lead compound in their Neuronal Nicotiic receptor program. The program is focussed on finding drugs for smoking cessation.

Filed under: Uncategorized | Tagged: agonist, GlaxoSmithkline, gpcr, GSK, Nicotinic, Targacept

« Can-Fite Adenosine receptor agonist CF102 completes Phase I trials QRx Pharma release positve Phase II results with Oxycodone/Morphine »

Leave a Reply